Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma research hub

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma

This study is looking at new treatments, relatlimab and nivolumab, for young people (up to 18 years old) with types of blood cancer called Hodgkin Lymphoma and Non-Hodgkin Lymphoma. It checks if they are safe and if they help shrink the cancer when other treatments haven't worked.